pyrazines has been researched along with Parkinson Disease in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Chen, H; Guo, B; Liu, Z; Sun, Y; Wang, P; Wang, Y; Zha, L; Zhang, G; Zhang, Z | 1 |
| Brown, TM; Dorka, N; Hochgeschwender, U; Medendorp, WE; Palmateer, B; Petersen, ED; Prakash, M; Wagner, LM; Zenchak, JR | 1 |
| Cheng, JJ; Chiou, CT; Huang, CL; Huang, HM; Huang, HT; Huang, NK; Lee, YC; Yang, JM; Yang, YC | 1 |
| Bonhaus, D; Khan, A; Koike, MA; Masliah, E; Price, DL; Rockenstein, E; Wrasidlo, W | 1 |
| Guo, B; Lee, SM; Li, C; Li, H; Lu, J; Lu, Y; Shao, M; Wang, Y; Yang, X; Zhang, Z; Zhong, H; Zhou, H; Zhu, Q | 1 |
| Du, J; Duan, H; Guo, B; Lee, SM; Wang, Y; Xu, D; Zhang, Z | 1 |
| Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L | 1 |
| Han, Y; Hu, S; Hu, Y; Lee, SM; Li, H; Li, Y; Mak, S; Wang, L; Wang, Y; Xu, D; Zhang, Z | 1 |
| Abdel-Tawab, AM; Esmat, A; Khalifa, AE; Michel, HE; Tadros, MG | 1 |
| Chang, H; Conlon, PR; Engber, TM; Haque, S; Kiesman, WF; Kumaravel, G; Petter, RC; Sha, L; Wang, J; Whalley, ET; Yao, G | 1 |
| Ayyub, E; Chang, HX; Dowling, JE; Engber, T; Haque, S; Jin, X; Kumaravel, G; Petter, RC; Phadke, D; van Vloten, K; Vessels, JT; Wang, J | 1 |
11 other study(ies) available for pyrazines and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson's disease models through activating the MEF2-PGC1α and BDNF/CREB pathways.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Hydrazones; MEF2 Transcription Factors; Mice; Neurogenesis; Neuroprotection; Neuroprotective Agents; Parkinson Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pyrazines; Rats; Signal Transduction; Treatment Outcome | 2020 |
Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.
Topics: Animals; Disease Models, Animal; Female; Imidazoles; Luminescent Agents; Luminescent Measurements; Luminescent Proteins; Male; Mice, Transgenic; Motor Activity; Neural Stem Cells; Opsins; Optogenetics; Parkinson Disease; Pyrazines; Rotarod Performance Test | 2020 |
LGK974, a PORCUPINE inhibitor, mitigates cytotoxicity in an in vitro model of Parkinson's disease by interfering with the WNT/β-CATENIN pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Cell Line; Cell Line, Tumor; Cell Survival; Glycogen Synthase Kinase 3; Humans; Immunohistochemistry; Paraquat; Parkinson Disease; Pyrazines; Pyridines; Wnt Signaling Pathway | 2018 |
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cerebral Cortex; Disease Models, Animal; Gene Expression Regulation; Humans; Inflammation; Lewy Body Disease; Mice; Mice, Transgenic; Multiple System Atrophy; Neurons; Parkinson Disease; Piperidines; Protein Aggregation, Pathological; Protein Folding; Pyrazines; Pyrimidines; Retina | 2018 |
Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Dose-Response Relationship, Drug; Humans; Hydrazones; Mice; Mice, Transgenic; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Pyrazines; Rats; Vasodilator Agents | 2019 |
Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Behavior, Animal; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Ligusticum; Male; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Oxidopamine; Parkinson Disease; Phytotherapy; Plant Extracts; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Substantia Nigra; Zebrafish | 2014 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |
Potent Protection Against MPP
Topics: Animals; Cell Line; Cells, Cultured; Drugs, Chinese Herbal; Enzyme Activation; MEF2 Transcription Factors; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphatidylinositol 3-Kinases; Pyrazines; Rats; Transcriptional Activation | 2016 |
Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Brain; Cyclooxygenase 2; Disease Models, Animal; Male; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrazines; Rats, Sprague-Dawley; Rotenone; Vasodilator Agents | 2017 |
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Cortex; Disease Models, Animal; Mice; Oxidopamine; Parkinson Disease; Pyrazines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain; Cell Membrane; Disease Models, Animal; Parkinson Disease; Pyrazines; Radioligand Assay; Rats; Structure-Activity Relationship | 2005 |